ClinicalTrials.gg
CompletedNCT01208090Updated Mar 30, 2025

ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis

A Phase 2 interventional study of ACT-128800 and Placebo in Psoriasis, sponsored by Actelion. Completed at 68 sites in 17 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
326
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Psoriasis by Johnson & Johnson — 3 open to participants now, 12 under way, 7 of them phase 3. Psoriasis · Johnson & Johnson.

Enrollment
21st of 58
326 · median 222
Started
2010
with 4 others
Phase 2
12 of 76
none open now
Registered
26th of 76
by date

Among the 76 studies in Psoriasis by Johnson & Johnson, this one is the 21st largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2010, is one of 12 in phase 2, and was the 26th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 76 studies in Psoriasis by Johnson & Johnson are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Psoriasis by Johnson & Johnson, or all of them as a file.
02

Study summary

This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • psoriasis
  • chronic plaque psoriasis
  • Moderate to severe chronic plaque psoriasis
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult males and females aged 18 to 60 years (inclusive) with moderate to severe chronic plaque psoriasis who require systemic treatment.

Exclusion criteria

Exclusion Criteria:

  • Patients with other forms of psoriasis and patients who are currently treated for disorders other than psoriasis.
  • Systemic or topical treatments for psoriasis other than emollients. Ongoing bacterial, viral or fungal infections.

History or presence of .

  • Additional inclusion and exclusion criteria apply with respect to medical conditions and concomitant treatments which could affect patients' risk from participating in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
326 participants (actual)

Study arms

  • Experimental
    Investigational drug - Dose 1

    Drug: ACT-128800

  • Experimental
    Investigational drug - Dose 2

    Drug: ACT-128800

  • Placebo comparator
    Matching placebo

    Drug: Placebo

Interventions

  • ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily

  • DrugPlacebo

    ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily

06

What researchers measure

Primary outcomes

  1. Proportion of patients with at least 75% improvement in PASI from baseline (PASI75) at Week 16.

    Time frame: Baseline to week 16

Secondary outcomes

  1. Proportion of patients with "Clear" or "Almost clear" on PGA at Week 16.

    Time frame: Baseline to week 16

07

Study locations

68 sites
  • Clinical Investigative Site 1006
    Feldkirch, 6807, Austria
  • Clinical Investigative Site 1002
    Graz, 8036, Austria
  • Clinical Investigative Site 1004
    St. Polten, 3100, Austria
  • Clinical Investigative Site 1007
    Vienna, 1130, Austria
  • Clinical Investigative Site 1001
    Vienna, A-1090, Austria
  • Clinical Investigative Site 1103
    Brussels, 1200, Belgium
  • Clinical Investigative Site 1102
    Edegem, 2650, Belgium
  • Clinical Investigative Site 1101
    Liege, 4000, Belgium
  • Clinical Investigative Site 1205
    Pleven, 5800, Bulgaria
  • Clinical Investigative Site 1204
    Plovdiv, 4002, Bulgaria
  • Clinical Investigative Site 1202
    Sofia, 1431, Bulgaria
  • Clinical Investigative Site 1201
    Sofia, 1606, Bulgaria
  • Clinical Investigative Site 1203
    Sofia, 1606, Bulgaria
  • Clinical Investigative Site 1206
    Stara Zagora, 6000, Bulgaria
  • Clinical Investigative Site 1402
    Hradec Kralove, 50005, Czechia
  • Clinical Investigative Site 1405
    Novy Jicin, 74101, Czechia
  • Clinical Investigative Site 1406
    Pardubice, 53203, Czechia
  • Clinical Investigative Site 1401
    Prague, 10034, Czechia
  • Clinical Investigative Site 1502
    Copenhagen, 2400, Denmark
  • Clinical Investigative Site 1504
    Roskilde, 4000, Denmark
  • Clinical Investigative Site 1704
    Bordeaux Cedex, 86021, France
  • Clinical Investigative Site 1701
    Nice, 06202, France
  • Clinical Investigative Site 1707
    Paris Cedex 10, 75475, France
  • Clinical Investigative Site 1710
    Paris Cedex 18, 75877, France
  • Clinical Investigative Site 1710
    Paris, 75877, France
  • Clinical Investigative Site 1705
    Pierre Benite, 69310, France
  • Clinical Investigative Site 1703
    Poitiers Cedex, 86021, France
  • Clinical Investigative Site 1702
    Saint Etienne Cedex, 42055, France
  • Clinical Investigative Site 2002
    Budapest, 1085, Hungary
  • Clinical Investigative Site 2001
    Debrecen, 4012, Hungary
  • Clinical Investigative Site 2006
    Miskolc, 3529, Hungary
  • Clinical Investigative Site 2005
    Pecs, 7624, Hungary
  • Clinical Investigative Site 2003
    Szeged, 6720, Hungary
  • Clinical Investigative Site 2004
    Veszprem, 8200, Hungary
  • Clinical Investigative Site 2315
    Ancona, 60020, Italy
  • Clinical Investigative Site 2303
    Bergamo, 24128, Italy
  • Clinical Investigative Site 2307
    Bologna, 40138, Italy
  • Clinical Investigative Site 2317
    Genova, 16132, Italy
  • Clinical Investigative Site 2309
    L'Aquila, 67100, Italy
  • Clinical Investigative Site 2310
    Pisa, 56126, Italy
  • Clinical Investigative Site 2304
    Roma, 00133, Italy
  • Clinical Investigative Site 2316
    Rome, 00168, Italy
  • Clinical Investigative Site 3801
    Vilnius, Lithuania
  • Clinical Investigative Site 2608
    Bucharest, 011461, Romania
  • Clinical Investigative Site 2601
    Bucharest, 020125, Romania
  • Clinical Investigative Site 2604
    Cluj-Napoca, 400006, Romania
  • Clinical Investigative Site 2603
    Iasi, 700368, Romania
  • Clinical Investigative Site 2606
    Oradea, 410167, Romania
  • Clinical Investigative Site 2607
    Sibiu, 550245, Romania
  • Clinical Investigative Site 2602
    Timisoara, 300074, Romania
  • Clinical Investigative Site 2605
    Tirgu-Mures, 540342, Romania
  • Clinical Investigative Site 3410
    Krasnodar, 350020, Russian Federation
  • Clinical Investigative Site 2704
    Banska Bystrica, 97517, Slovakia
  • Clinical Investigative Site 2705
    Kosice-Saca, 04015, Slovakia
  • Clinical Investigative Site 2701
    Kosice, 04166, Slovakia
  • Clinical Investigative Site 2708
    Trnava, 91775, Slovakia
  • Clinical Investigative Site 2901
    Barcelona, 08025, Spain
  • Clinical Investigative Site 2907
    Las Palmas de Gran Canaria, Spain
  • Clinical Investigative Site 2902
    Madrid, 28041, Spain
  • Clinical Investigative Site 2904
    Madrid, 28922, Spain
  • Clinical Investigative Site 3001
    Stockholm, 17176, Sweden
  • Clinical Investigative Site 3006
    Umea, 90185, Sweden
  • Clinical Investigative Site 3101
    Lausanne, 1011, Switzerland
  • Clinical Investigative Site 3103
    Zurich, 8091, Switzerland
  • Clinical Investigative Site 3512
    Poltava, 36038, Ukraine
  • Clinical Investigative Site 3514
    Zaporizhia, 69063, Ukraine
  • Clinical Investigative Site 3306
    Dundee, DD1 9SY, United Kingdom
  • Clinical Investigative Site 3304
    London, E11 1NR, United Kingdom
08

References and documents

Publications

  • Vaclavkova A, Chimenti S, Arenberger P, Hollo P, Sator PG, Burcklen M, Stefani M, D'Ambrosio D. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014 Dec 6;384(9959):2036-45. doi: 10.1016/S0140-6736(14)60803-5. Epub 2014 Aug 10. PubMed 25127208 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2010 to primary completion in Oct 2012, 24 months.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 24 months is above that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2010
First posted
Sep 23, 2010
StartActual
Oct 31, 2010
Primary completionActual
Oct 31, 2012
CompletionActual
Nov 30, 2012
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01208090
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Sep 23, 2010
Start date
Oct 31, 2010
Primary completion
Oct 31, 2012
Completion
Nov 30, 2012
Last update
Mar 30, 2025

Study contacts

Actelion Pharmaceuticals
study director · Actelion
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ponesimod

Start the discussion